| Medical and Health Sciences | Lifetime | 474 | GB 51 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 249 | GB 27 | 99.95 |
| Pulmonary and Respiratory Medicine | Lifetime | 13 | GB 1 | 99.98 |
| Oncology | Lifetime | 54 | GB 3 | 99.91 |
| Cancer Research | Lifetime | 136 | GB 14 | 99.25 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 482 | GB 41 | 98.80 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 16 | GB 2 | 99.93 |
| Oncology | 2021-2025 | 69 | GB 2 | 99.62 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 213 | GB 16 | 95.97 |
| Cancer Research | 2021-2025 | 127 | GB 7 | 93.90 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 1 | GB 1 | 99.95 |
| Prostate Cancer Treatment and Research | Lifetime | 2 | GB 1 | 99.98 |
| PARP inhibition in cancer therapy | Lifetime | 1 | GB 1 | 99.90 |
| Cancer, Lipids, and Metabolism | Lifetime | 11 | GB 1 | 99.91 |
| Cancer Genomics and Diagnostics | Lifetime | 42 | GB 7 | 99.87 |
| Cancer Treatment and Pharmacology | Lifetime | 43 | GB 2 | 99.82 |
| Cancer Cells and Metastasis | Lifetime | 46 | GB 3 | 99.63 |
| Multiple Myeloma Research and Treatments | Lifetime | 51 | GB 2 | 99.63 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 52 | GB 6 | 99.45 |
| Hormonal and reproductive studies | Lifetime | 106 | GB 7 | 99.20 |
| Cancer therapeutics and mechanisms | Lifetime | 130 | GB 9 | 99.14 |
| Lung Cancer Treatments and Mutations | Lifetime | 337 | GB 14 | 99.16 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 373 | GB 13 | 99.12 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 413 | GB 26 | 98.82 |
| Protein Degradation and Inhibitors | Lifetime | 123 | GB 3 | 98.93 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 205 | GB 16 | 99.30 |
| Peptidase Inhibition and Analysis | Lifetime | 364 | GB 22 | 98.58 |
| DNA Repair Mechanisms | Lifetime | 303 | GB 30 | 98.45 |
| Cancer Research and Treatments | Lifetime | 307 | GB 16 | 98.15 |
| HER2/EGFR in Cancer Research | Lifetime | 250 | GB 19 | 98.91 |
| Histone Deacetylase Inhibitors Research | Lifetime | 181 | GB 7 | 98.11 |
| Ubiquitin and proteasome pathways | Lifetime | 440 | GB 36 | 98.01 |
| Colorectal Cancer Treatments and Studies | Lifetime | 597 | GB 31 | 98.26 |
| Cancer-related Molecular Pathways | Lifetime | 715 | GB 64 | 97.65 |
| Advanced Breast Cancer Therapies | Lifetime | 297 | GB 18 | 97.57 |
| Cancer Mechanisms and Therapy | Lifetime | 374 | GB 13 | 96.19 |
| Statistical Methods in Clinical Trials | Lifetime | 687 | GB 97 | 93.36 |
| Clusterin in disease pathology | Lifetime | 357 | GB 25 | 69.33 |
| Prostate Cancer Treatment and Research | 2021-2025 | 3 | GB 1 | 99.94 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 5 | GB 1 | 99.81 |
| PARP inhibition in cancer therapy | 2021-2025 | 12 | GB 1 | 99.55 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 32 | GB 3 | 99.11 |
| DNA Repair Mechanisms | 2021-2025 | 43 | GB 9 | 96.49 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 352 | GB 10 | 98.65 |
| Cancer Genomics and Diagnostics | 2021-2025 | 320 | GB 22 | 97.69 |
| Ubiquitin and proteasome pathways | 2021-2025 | 119 | GB 4 | 94.39 |
| Peptidase Inhibition and Analysis | 2021-2025 | 437 | GB 16 | 92.15 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 471 | GB 21 | 93.72 |
| Cancer-related Molecular Pathways | 2021-2025 | 333 | GB 14 | 85.76 |
| Cell death mechanisms and regulation | 2021-2025 | 92 | GB 5 | 84.97 |
| Advanced Breast Cancer Therapies | 2021-2025 | 604 | GB 21 | 89.00 |
| Protein Degradation and Inhibitors | 2021-2025 | 932 | GB 40 | 84.86 |
| Statistical Methods in Clinical Trials | 2021-2025 | 408 | GB 64 | 81.04 |
| Meta-analysis and systematic reviews | 2021-2025 | 709 | GB 128 | 74.12 |
| Chemokine receptors and signaling | 2021-2025 | 674 | GB 26 | 55.90 |
